Rafeh Naqash, A. et al. 2018. Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report. Acta Oncologica. 57, 5 (May 2018), 705–708. DOI:https://doi.org/10.1080/0284186X.2017.1406668.